AstraZeneca completes U.S. licensing agreement for Zurampic
Zirampic has received approval in the U.S. when combined with an inhibitor called xanthine oxidase. It is used to treat hyperuricemia, which is related to uncontrolled gout. Now the fixed-dose combination will need to pass regulatory review during the second half of this year.
AstraZeneca, a worldwide biopharmaceutical company, is driven by innovation. It is dedicated to finding, creating and selling prescription drugs. Most of its drugs are used to treat diseases involving inflammation, the respiratory system, cardiovascular health, autoimmune diseases (RIA) and metabolic diseases (CVMD). The drugs are also used in the oncology field. Some of the company’s treatments can be used in neuroscience and in different kinds of infections.
As of today, AstraZeneca has health authority in more than 100 nations around the world. Countless patients living across the globe use the company’s innovative new medicines to treat various health concerns. Adding the new licensing agreement to the company’s portfolio will extend AstraZeneca’s reach even further across the globe into new fields of health.
Organizations in this story
AstraZeneca Pharmaceuticals LP 1800 Concord Pike Wilmington, DE 19803